Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SK-NK Injection for Advanced Solid Tumors with Malignant Ascites
NCT06991478Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
A Phase 2 trial of SK-NK cell injection in solid tumor, malignant ascites, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start May 2025; status: not yet recruiting.
02
Drugs
SK-NK cell injection
03
Conditions
solid tumormalignant ascites
Beyond the preview
Go deeper on NCT06991478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991478.